Atai Life Sciences Future Growth

Future criteria checks 2/6

Atai Life Sciences is forecast to grow earnings and revenue by 34.6% and 82.3% per annum respectively. EPS is expected to grow by 46.2% per annum. Return on equity is forecast to be -129.6% in 3 years.

Key information

34.6%

Earnings growth rate

46.2%

EPS growth rate

Pharmaceuticals earnings growth21.5%
Revenue growth rate82.3%
Future return on equity-129.6%
Analyst coverage

Good

Last updated18 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:9VC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20260-138-148-1436
12/31/20250-119-121-1166
12/31/20241-129-85-846
9/30/20240-129-80-80N/A
6/30/20240-58-79-79N/A
3/31/20240-34-86-86N/A
12/31/20230-40-85-84N/A
9/30/20230-67-93-93N/A
6/30/20230-145-104-102N/A
3/31/20230-149-103-102N/A
12/31/20220-152-105-104N/A
9/30/20220-196-97-94N/A
6/30/20221-194-96-95N/A
3/31/20220-205-73-71N/A
12/31/202120-168-65-63N/A
9/30/202120-166-50-49N/A
6/30/202120-218-27-26N/A
3/31/202120-185-34-33N/A
12/31/2020N/A-170-21-21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9VC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 9VC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 9VC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 9VC's revenue (82.3% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: 9VC's revenue (82.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 9VC is forecast to be unprofitable in 3 years.


Discover growth companies